Individuals who inherited mutations conferring high cancer risks should ideally be identified before they ever develop cancer. Such mutation carriers stand to reap the greatest benefit from surveillance and prevention measures. This begs the question of the optimal means of identifying such carriers. ...
Cancer is a rapidly growing burden on healthcare. To turn the tide, science and society must unite to accelerate therapeutic breakthroughs — and change the way they’re delivered.
Moreover, prognosis is related to how cancer is identified, and where in the healthcare system patients present, i.e. routes to diagnosis (RtD). We investigated whether RtD varied by patients' age. Methods: This population-based national cohort study used Danish registry data. Patients ...
So today, Laurence Edmondson joins David Dennis Jr. to explain all the drama from the garage to the track and tells us why the resurgence of F1 is just getting started. You can honor Jim Valvano and support ESPN's V Week with a donation to the V Foundation for Cancer Research....
The best of National Geographic delivered to your inbox Sign up for more inspiring photos, stories, and special offers from National Geographic.Sign Up Legal Terms of Use Privacy Policy Interest-Based Ads Our Sites Nat Geo Home Attend a Live Event Book a Trip Buy Maps Inspire Your Kids ...
It can be further identified as carcinoma-in-situ namely ductal carcinoma-in-situ (DCIS) and lobular carcinoma-in-situ (LCIS), and invasive breast carcinoma. The DCIS or intra-ductal carcinoma affects the lining of the milk ducts and has not invaded nearby tissues but regarded as a true ...
A day before her 28th birthday, Dana Donofree was diagnosed with breast cancer. With few post-mastectomy bra options on the market, she launched her own intimates brand, AnaOno. Meet Dana and two other founders catering to cancer survivors under 40 — a
The results showed that using AI to analyze CT scans of tissue identified biomarkers that could show which of the 109 non-small cell lung cancer patients in the study would experience tumor growth from immunotherapy. In 5 to 10 years’ time, I hope we will see personalised immunotherapy. This...
In this issue of the Journal of Genetic Counseling, Robert Resta comments about the daunting prospect of re-contacting all our patients who have tested negative for BRCA1 and BRCA2 mutations when and if another major breast cancer susceptibility gene is identified. Luckily, we have been faced ...
This work is supported by the US National Institutes of Health (NIH), the Juvenile Diabetes Research Foundation (JDRF), a Cancer Center Support CORE grant and the American Lebanese Syrian Associated Charities (ALSAC). We apologize to those authors whose work we could not cite due to space ...